|
Signal transduction regulating tumor cell dissemination
|
5R01CA150344-30
|
$396,625
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-05
|
$341,059
|
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics
|
5R01CA205594-02
|
$362,569
|
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel therapeutics for targeting checkpoint dysfunction in cancer
|
5R01CA203824-02
|
$362,569
|
|
LIN, WEEI-CHIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE ROLE OF TELOMERASE REGULATORS IN TELOMERE MAINTENANCE AND GENOMIC INSTABILITY
|
5R01CA211653-02
|
$362,569
|
|
SONGYANG, ZHOU
|
BAYLOR COLLEGE OF MEDICINE
|
|
De facto Target of Histone Deacetylase Inhibitors
|
5R21CA215591-02
|
$172,369
|
|
SUN, ZHENG
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeted activation of autoimmune checkpoints in B cell malignancies
|
5R01CA157644-09
|
$410,875
|
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
|
5R21CA205106-02
|
$176,605
|
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Personalized vaccine for patients with AML
|
5R01CA212649-02
|
$721,179
|
|
AVIGAN, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
SOX9 Mediation of AR and ERG Driven Prostate Cancer
|
5R01CA168393-05
|
$361,050
|
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting PML for Leukemia Therapy
|
5R01CA142874-08
|
$457,619
|
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
(PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment
|
5R01CA205431-03
|
$522,325
|
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit
|
5R01CA200671-03
|
$395,738
|
|
TOKER, ALEX
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Passive and active targeting of unnatural chemokine fusions for cancer immunotherapies
|
1F32CA220990-01
|
$61,174
|
|
FANG, TAO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
5R01CA211328-02
|
$404,888
|
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Cancer Deep Phenotype Extraction from Electronic Medical Records
|
5U24CA184407-06
|
$993,015
|
|
SAVOVA, GUERGANA
|
BOSTON CHILDREN'S HOSPITAL
|
|
Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor
|
5R01CA211646-02
|
$411,481
|
|
ZETTER, BRUCE
|
BOSTON CHILDREN'S HOSPITAL
|
|
Characterization of Thyroid Nodules by Quantitative Ultrasound
|
5R21CA212744-02
|
$190,102
|
|
LEE, STEPHANIE
|
BOSTON MEDICAL CENTER
|
|
Development of diagnostic and prognostic tests for esophageal adenocarcinoma
|
5R01CA208599-02
|
$603,464
|
|
GODFREY, TONY
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Accelerating Cancer Genomics with Cloud-scale Bioconductor
|
5U01CA214846-02
|
$438,654
|
|
CAREY, VINCENT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
How does malignancy subvert platelet and megakaryocytic biology?
|
5R01CA200748-02
|
$550,945
|
|
ITALIANO, JOSEPH
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment
|
5R01CA203636-02
|
$567,838
|
|
NISHINO, MIZUKI
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
PatientCareAnywhere: Patient Support and Empowerment Across the Care Continuum
|
5R44CA192588-04
|
$234,573
|
|
YANG, DERSHUNG
|
BRIGHTOUTCOME INC.
|
|
tDCS for Increasing Exercise Adherence in Individuals with Elevated Depressive Symptoms
|
5R21CA214102-02
|
$154,969
|
|
ABRANTES, ANA
|
BUTLER HOSPITAL (PROVIDENCE, RI)
|
|
Diet-Associated Gut Microbiome Signatures and Risk of Colon Adenoma
|
5R03CA212558-02
|
$79,250
|
|
LI, LI
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
|
5R35CA197442-02
|
$951,000
|
|
MARKOWITZ, SANFORD
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Mechanisms of metabolic reprogramming by PIK3CA oncogenic mutations
|
5R01CA196643-03
|
$383,725
|
|
WANG, ZHENGHE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Functional Effects of Ovarian Cancer Risk Variants
|
5R01CA211707-02
|
$622,079
|
|
GAYTHER, SIMON
|
CEDARS-SINAI MEDICAL CENTER
|
|
High resolution volumetric MRI for prostate cancer active surveillance
|
5R01CA217098-02
|
$379,039
|
|
KIM, HYUNG
|
CEDARS-SINAI MEDICAL CENTER
|
|
Nanoconjugate delivery of proliferation and checkpoint inhibitors to treat glial tumors
|
5R01CA206220-03
|
$547,857
|
|
LJUBIMOVA, JULIA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Improving risk allocation and developing novel therapies for children with T-ALL
|
5R01CA193776-04
|
$594,741
|
|
TEACHEY, DAVID
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Patient Preferences and Adherence in Adolescents and Young Adults with Cancer
|
5K07CA200668-03
|
$144,855
|
|
MCGRADY, MEGHAN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Novel mechanisms and therapeutic strategies of refractory leukemia
|
5F31CA217140-02
|
$37,204
|
|
MELGAR, KATELYN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeting Cdc42 for bone marrow transplant therapies
|
5R01CA193350-04
|
$356,850
|
|
ZHENG, YI
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Microenvironment Interleukin-17 and Colorectal Cancer Treatment Resistance
|
5R01CA193359-04
|
$362,569
|
|
KALADY, MATTHEW
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Nanoparticle-mediated treatment for bone metastasis
|
5R01CA206189-03
|
$312,562
|
|
LABHASETWAR, VINOD
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Vitamin D and Photodynamic Therapy for Human Skin Cancer (SCC and BCC)
|
5R01CA204158-02
|
$463,965
|
|
MAYTIN, EDWARD
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Role of MIF in myeloma bone homing and drug response
|
5R01CA211073-02
|
$362,569
|
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Protein Tyrosine Dephosphorylation & Signal Transduction
|
5R01CA053840-27
|
$776,676
|
|
TONKS, NICHOLAS
|
COLD SPRING HARBOR LABORATORY
|
|
Roles and Regulation of wild-type and mutant forms of p53
|
5P01CA087497-17
|
$1,885,586
|
|
PRIVES, CAROL
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Molecular mechanisms of prostate cancer metastasis
|
5R01CA183929-04
|
$366,000
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-04
|
$366,000
|
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of the LZTR1 ubiquitin ligase in stem cells and cancer
|
5R01CA190891-04
|
$383,079
|
|
IAVARONE, ANTONIO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Topology of Cancer Evolution and Heterogeneity
|
5U54CA193313-04
|
$2,030,348
|
|
RABADAN, RAUL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer
|
1U01CA225431-01
|
$644,727
|
|
SCHWARTZ, LAWRENCE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of wild-type KRAS in the context of tumor profession and metastasis
|
5R01CA178445-04
|
$450,563
|
|
SU, GLORIA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of Stem Cells and the Microenvironment in Gastrointestinal Cancers
|
5R35CA210088-02
|
$912,000
|
|
WANG, TIMOTHY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Origins of Ovarian Carcinoma
|
5R01CA182413-04
|
$421,580
|
|
NIKITIN, ALEXANDER
|
CORNELL UNIVERSITY
|
|
Mediastinal Lymph Node Identification in Lung Cancer using NIR Fluorescent VATS
|
5R01CA207500-02
|
$743,574
|
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
|
ZW800-1: The 1st Zwitterionic NIR Fluorophore for Cancer Imaging & Ureter Mapping
|
5R44CA210820-02
|
$989,401
|
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
Total relevant funding to Salivary Glands for this search: $678,015
|